Pipeline

Vernalis entered into a development and licensing deal with Tris Pharma, Inc, in February 2012, obtaining exclusive rights to Tris’ extended-release technology for use in the US prescription cough cold market with approximately 30-35 million prescriptions annually, it is potentially worth over $3 billion at 2015 brand pricing. 

In October 2015, Vernalis also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older.

To see the status of these programmes at a glance – roll over any listing or click on it to find out more.

 

 

Click here for more details on Tuzistra® XR, (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III), the full US Prescribing Information including Boxed Warning and Medication Guide.

Click here for more details on Moxatag® and including full US Prescribing Information.

Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch